Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

NF-kappa B genes have a major role in Inflammatory Breast Cancer

Authors: Florence Lerebours, Sophie Vacher, Catherine Andrieu, Marc Espie, Michel Marty, Rosette Lidereau, Ivan Bieche

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

IBC (Inflammatory Breast cancer) is a rare form of breast cancer with a particular phenotype. New molecular targets are needed to improve the treatment of this rapidly fatal disease. Given the role of NF-κB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated in IBC.

Methods

We measured the mRNA expression levels of 60 NF-κB-related genes by using real-time quantitative RT-PCR in a well-defined series of 35 IBCs, by comparison with 22 stage IIB and III non inflammatory breast cancers. Twenty-four distant metastases of breast cancer served as "poor prognosis" breast tumor controls.

Results

Thirty-five (58%) of the 60 NF-κB-related genes were significantly upregulated in IBC compared with non IBC. The upregulated genes were NF-κB genes (NFKB1, RELA, IKBKG, NFKBIB, NFKB2, REL, CHUK), apoptosis genes (MCL1L, TNFAIP3/A20, GADD45B, FASLG, MCL1S, IER3L, TNFRSF10B/TRAILR2), immune response genes (CD40, CD48, TNFSF11/RANKL, TNFRSF11A/RANK, CCL2/MCP-1, CD40LG, IL15, GBP1), proliferation genes (CCND2, CCND3, CSF1R, CSF1, SOD2), tumor-promoting genes (CXCL12, SELE, TNC, VCAM1, ICAM1, PLAU/UPA) or angiogenesis genes (PTGS2/COX2, CXCL1/GRO1). Only two of these 35 genes (PTGS2/COX2 and CXCL1/GRO1)were also upregulated in breast cancer metastases. We identified a five-gene molecular signature that matched patient outcomes, consisting of IL8 and VEGF plus three NF-κB-unrelated genes that we had previously identified as prognostic markers in the same series of IBC.

Conclusion

The NF-κB pathway appears to play a major role in IBC, possibly contributing to the unusual phenotype and aggressiveness of this form of breast cancer. Some upregulated NF-κB-related genes might serve as novel therapeutic targets in IBC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol. 1992, 10: 1014-1024.PubMed Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol. 1992, 10: 1014-1024.PubMed
2.
go back to reference Delarue JC, May-Levin F, Mouriesse H, Contesso G, Sancho-Garnier H: Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer. 1981, 44 (6): 911-916.CrossRefPubMedPubMedCentral Delarue JC, May-Levin F, Mouriesse H, Contesso G, Sancho-Garnier H: Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer. 1981, 44 (6): 911-916.CrossRefPubMedPubMedCentral
3.
go back to reference Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989, 43: 201-208. 10.1002/ijc.2910430205.CrossRefPubMed Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989, 43: 201-208. 10.1002/ijc.2910430205.CrossRefPubMed
4.
go back to reference Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 1989, 64: 1922-1927. 10.1002/1097-0142(19891101)64:9<1922::AID-CNCR2820640927>3.0.CO;2-I.CrossRefPubMed Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 1989, 64: 1922-1927. 10.1002/1097-0142(19891101)64:9<1922::AID-CNCR2820640927>3.0.CO;2-I.CrossRefPubMed
5.
go back to reference Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, Vidaud M, de The H: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002, 21: 7593-7597. 10.1038/sj.onc.1205932.CrossRefPubMed Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, Vidaud M, de The H: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002, 21: 7593-7597. 10.1038/sj.onc.1205932.CrossRefPubMed
7.
go back to reference Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Jonhsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Jonhsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
8.
go back to reference Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.CrossRefPubMedPubMedCentral Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.CrossRefPubMedPubMedCentral
9.
go back to reference Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Jacquemier J, Houlgatte R, Birnbaum D, Viens P: Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Res. 2004, 64: 8558-8565. 10.1158/0008-5472.CAN-04-2696.CrossRefPubMed Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Jacquemier J, Houlgatte R, Birnbaum D, Viens P: Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Res. 2004, 64: 8558-8565. 10.1158/0008-5472.CAN-04-2696.CrossRefPubMed
10.
go back to reference Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005, 93: 237-246. 10.1007/s10549-005-5157-z.CrossRefPubMed Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005, 93: 237-246. 10.1007/s10549-005-5157-z.CrossRefPubMed
11.
go back to reference Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC: Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006, 12: 5047-5054. 10.1158/1078-0432.CCR-05-2248.CrossRefPubMed Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC: Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006, 12: 5047-5054. 10.1158/1078-0432.CCR-05-2248.CrossRefPubMed
12.
go back to reference Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006, 12: 3249-3256. 10.1158/1078-0432.CCR-05-2800.CrossRefPubMed Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006, 12: 3249-3256. 10.1158/1078-0432.CCR-05-2800.CrossRefPubMed
13.
go back to reference Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004, 10: 6789-6795. 10.1158/1078-0432.CCR-04-0306.CrossRefPubMed Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004, 10: 6789-6795. 10.1158/1078-0432.CCR-04-0306.CrossRefPubMed
14.
go back to reference Aggarwal BB: Nuclear factor-kappaB the enemy within. Cancer Cell. 2004, 6: 203-208. 10.1016/j.ccr.2004.09.003.CrossRefPubMed Aggarwal BB: Nuclear factor-kappaB the enemy within. Cancer Cell. 2004, 6: 203-208. 10.1016/j.ccr.2004.09.003.CrossRefPubMed
15.
go back to reference Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.CrossRefPubMed Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.CrossRefPubMed
16.
go back to reference Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehard JD: NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA. 2004, 101: 10137-10142. 10.1073/pnas.0403621101.CrossRefPubMedPubMedCentral Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehard JD: NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA. 2004, 101: 10137-10142. 10.1073/pnas.0403621101.CrossRefPubMedPubMedCentral
17.
go back to reference Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003, 8: 215-223. 10.1023/A:1025905008934.CrossRefPubMed Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003, 8: 215-223. 10.1023/A:1025905008934.CrossRefPubMed
18.
go back to reference Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000, 19: 1123-1131. 10.1038/sj.onc.1203412.CrossRefPubMed Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000, 19: 1123-1131. 10.1038/sj.onc.1203412.CrossRefPubMed
19.
go back to reference Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T: NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004, 114: 569-581. 10.1172/JCI200421358.CrossRefPubMedPubMedCentral Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T: NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004, 114: 569-581. 10.1172/JCI200421358.CrossRefPubMedPubMedCentral
20.
go back to reference Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997, 17: 3629-3639.CrossRefPubMedPubMedCentral Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997, 17: 3629-3639.CrossRefPubMedPubMedCentral
21.
go back to reference Shishodia S, Aggarwal BB: Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res. 2004, 119: 139-173.CrossRefPubMed Shishodia S, Aggarwal BB: Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res. 2004, 119: 139-173.CrossRefPubMed
22.
go back to reference Sarrazin D, Rouesse J, Arriagada R, May-Levin F, Petit JY, Contesso G: [Breast cancers in the evolutive phase]. Rev Prat. 1978, 28: 999-1009.PubMed Sarrazin D, Rouesse J, Arriagada R, May-Levin F, Petit JY, Contesso G: [Breast cancers in the evolutive phase]. Rev Prat. 1978, 28: 999-1009.PubMed
23.
go back to reference Mann H, Whitney D: On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat. 1947, 18: 50-60. 10.1214/aoms/1177730491.CrossRef Mann H, Whitney D: On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat. 1947, 18: 50-60. 10.1214/aoms/1177730491.CrossRef
24.
go back to reference Didier G, Brezellec P, Remy E, Henaut A: GeneANOVA-gene expression analysis of variance. Bioinformatics. 2002, 18: 490-491. 10.1093/bioinformatics/18.3.490.CrossRefPubMed Didier G, Brezellec P, Remy E, Henaut A: GeneANOVA-gene expression analysis of variance. Bioinformatics. 2002, 18: 490-491. 10.1093/bioinformatics/18.3.490.CrossRefPubMed
25.
go back to reference Cristofanilli M, Buzdar AU, Hortobagyi GN: Update on the management of inflammatory breast cancer. Oncologist. 2003, 8: 141-148. 10.1634/theoncologist.8-2-141.CrossRefPubMed Cristofanilli M, Buzdar AU, Hortobagyi GN: Update on the management of inflammatory breast cancer. Oncologist. 2003, 8: 141-148. 10.1634/theoncologist.8-2-141.CrossRefPubMed
26.
go back to reference Smith I: Goals of treatment for patients with metastatic breast cancer. Semin Oncol. 2006, 33: 2S-5S. 10.1053/j.seminoncol.2005.07.030.CrossRef Smith I: Goals of treatment for patients with metastatic breast cancer. Semin Oncol. 2006, 33: 2S-5S. 10.1053/j.seminoncol.2005.07.030.CrossRef
27.
go back to reference Anderson WF, Chu KC, Chang S: Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol. 2003, 21: 2254-2259. 10.1200/JCO.2003.07.082.CrossRefPubMed Anderson WF, Chu KC, Chang S: Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol. 2003, 21: 2254-2259. 10.1200/JCO.2003.07.082.CrossRefPubMed
28.
go back to reference Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH: Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005, 97: 966-975.CrossRefPubMedPubMedCentral Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH: Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005, 97: 966-975.CrossRefPubMedPubMedCentral
29.
go back to reference Luker KE, Luker GD: Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006, 238: 30-41. 10.1016/j.canlet.2005.06.021.CrossRefPubMed Luker KE, Luker GD: Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006, 238: 30-41. 10.1016/j.canlet.2005.06.021.CrossRefPubMed
30.
go back to reference Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002, 55: 429-434.CrossRefPubMedPubMedCentral Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002, 55: 429-434.CrossRefPubMedPubMedCentral
31.
go back to reference Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924.CrossRefPubMed Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924.CrossRefPubMed
32.
go back to reference Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Espie M, Marty M, Lidereau R: Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res. 2003, 9: 4184-4189.PubMed Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Espie M, Marty M, Lidereau R: Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res. 2003, 9: 4184-4189.PubMed
33.
go back to reference Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K: Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005, 11: 1287-1293.PubMed Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K: Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005, 11: 1287-1293.PubMed
34.
go back to reference Tanaka A, Muto S, Konno M, Itai A, Matsuda H: A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006, 66: 419-426. 10.1158/0008-5472.CAN-05-0741.CrossRefPubMed Tanaka A, Muto S, Konno M, Itai A, Matsuda H: A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006, 66: 419-426. 10.1158/0008-5472.CAN-05-0741.CrossRefPubMed
35.
go back to reference Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD: Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003, 2: 617-622.PubMed Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD: Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003, 2: 617-622.PubMed
36.
go back to reference Pan Q, Bao LW, Merajver SD: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003, 1: 701-706.PubMed Pan Q, Bao LW, Merajver SD: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003, 1: 701-706.PubMed
Metadata
Title
NF-kappa B genes have a major role in Inflammatory Breast Cancer
Authors
Florence Lerebours
Sophie Vacher
Catherine Andrieu
Marc Espie
Michel Marty
Rosette Lidereau
Ivan Bieche
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-41

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine